Startseite>>Signaling Pathways>> GPCR/G protein>> CCR>>CCR4 antagonist 2

CCR4 antagonist 2

Katalog-Nr.GC35626

CCR4-Antagonist 2 (Verbindung 31) ist ein neuartiger potenter, oral bioverfÜgbarer, niedermolekularer Antagonist des CC-Chemokinrezeptors 4 (CCR4), der den Transport von Treg in die Tumormikroumgebung hemmt, ohne die Anzahl von Treg in gesunden Geweben zu unterdrÜcken.

Products are for research use only. Not for human use. We do not sell to patients.

CCR4 antagonist 2 Chemische Struktur

Cas No.: 2206788-99-8

Größe Preis Lagerbestand Menge
100mg Please Inquire Please Inquire
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits Treg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues.CCR4 antagonist 2 (Compound 31) exhibits IC50 values of Ca2+flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively[1]. IC50: 40 nM (Ca2+flux); 70 nM (CTX) (CCR4 antagonist 2)[1]

[1]. Jackson JJ, et al. Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment. J Med Chem. 2019 Jul 11;62(13):6190-6213.

Bewertungen

Review for CCR4 antagonist 2

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CCR4 antagonist 2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.